Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia 2Primary Myelofibrosis 1Multiple Myeloma 1Leukemia, Monocytic, Acute 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Clonal Cytopenia of Undetermined Significance 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 21Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioma × enasidenib × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡